{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:35:31Z","timestamp":1793378131406,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.rmed.2026.109059","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:20:31Z","timestamp":1785169231000},"page":"109059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immunosuppressive medication patterns in rheumatoid arthritis\u2013associated interstitial lung disease by antifibrotic documentation status: A multicenter U.S. electronic health record study"],"prefix":"10.1016","volume":"261","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4113-2221","authenticated-orcid":false,"given":"Giorgos","family":"Loizidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3616-3917","authenticated-orcid":false,"given":"Pankhuri","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0351-2637","authenticated-orcid":false,"given":"Michael","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Summer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.rmed.2026.109059_bib1","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study","volume":"62","author":"Bongartz","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.rmed.2026.109059_bib2","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1002\/acr.24856","article-title":"Incidence, risk factors, and mortality of clinical and subclinical rheumatoid arthritis\u2013associated interstitial lung disease: a population-based cohort","volume":"74","author":"Samhouri","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.rmed.2026.109059_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2026-006934","article-title":"Validation of screening criteria for interstitial lung disease in rheumatoid arthritis in routine clinical practice: the VAR-EPIDSER study","volume":"12","author":"Mena-V\u00e1zquez","year":"2026","journal-title":"RMD Open"},{"issue":"5","key":"10.1016\/j.rmed.2026.109059_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103056","article-title":"Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis\u2013associated interstitial lung disease","volume":"21","author":"Akiyama","year":"2022","journal-title":"Autoimmun. Rev."},{"issue":"17","key":"10.1016\/j.rmed.2026.109059_bib5","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.3390\/diagnostics14171890","article-title":"A systematic review of the key predictors of progression and mortality of rheumatoid arthritis\u2013associated interstitial lung disease","volume":"14","author":"Groseanu","year":"2024","journal-title":"Diagnostics (Basel)"},{"issue":"18","key":"10.1016\/j.rmed.2026.109059_bib6","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.rmed.2026.109059_bib7","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"9","key":"10.1016\/j.rmed.2026.109059_bib8","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s10067-023-06623-7","article-title":"Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial","volume":"42","author":"Matteson","year":"2023","journal-title":"Clin. Rheumatol."},{"issue":"8","key":"10.1016\/j.rmed.2026.109059_bib9","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.42861","article-title":"American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2023","journal-title":"Arthritis Rheumatol."},{"issue":"9","key":"10.1016\/j.rmed.2026.109059_bib10","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.40904","article-title":"Rheumatoid arthritis disease activity predicting incident clinically-apparent RA-associated interstitial lung disease: a prospective cohort study","volume":"71","author":"Sparks","year":"2019","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"10.1016\/j.rmed.2026.109059_bib11","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s10067-021-06040-8","article-title":"Rheumatoid arthritis-related interstitial lung disease (RA-ILD): a possible association between disease activity and prognosis","volume":"41","author":"Rojas-Serrano","year":"2022","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.rmed.2026.109059_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152710","article-title":"Real-world evidence of the antifibrotic nintedanib in rheumatoid arthritis-interstitial lung disease. National multicenter study of 74 patients","volume":"72","author":"Atienza-Mateo","year":"2025","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.rmed.2026.109059_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152312","article-title":"Effectiveness and tolerability of antifibrotics in rheumatoid arthritis\u2013associated interstitial lung disease","volume":"64","author":"Juge","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.rmed.2026.109059_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"issue":"1","key":"10.1016\/j.rmed.2026.109059_bib15","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s13075-020-02310-z","article-title":"Use of ICD-10 diagnosis codes to identify seropositive and seronegative rheumatoid arthritis when lab results are not available","volume":"22","author":"Curtis","year":"2020","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.rmed.2026.109059_bib16","doi-asserted-by":"crossref","DOI":"10.1186\/ar3260","article-title":"Validation of rheumatoid arthritis diagnoses in health care utilization data","volume":"13","author":"Kim","year":"2011","journal-title":"Arthritis Res. Ther."},{"issue":"5","key":"10.1016\/j.rmed.2026.109059_bib17","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/pds.5597","article-title":"Validation of serostatus of rheumatoid arthritis using ICD-10 codes in administrative claims data","volume":"32","author":"Lee","year":"2023","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"10","key":"10.1016\/j.rmed.2026.109059_bib18","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/acr.24043","article-title":"Performance of administrative algorithms to identify interstitial lung disease in rheumatoid arthritis","volume":"72","author":"England","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.rmed.2026.109059_bib19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ard.2025.08.021","article-title":"ERS\/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease","volume":"85","author":"Antoniou","year":"2026","journal-title":"Ann. Rheum. Dis."},{"issue":"23","key":"10.1016\/j.rmed.2026.109059_bib20","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1801562","article-title":"MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease","volume":"379","author":"Juge","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2026.109059_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.106943","article-title":"Associations between shortened telomeres and rheumatoid arthritis\u2013associated interstitial lung disease among US Veterans","volume":"201","author":"Natalini","year":"2022","journal-title":"Respir. Med."},{"issue":"4","key":"10.1016\/j.rmed.2026.109059_bib22","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/rheumatology\/keab552","article-title":"The attitudes and practices of physicians caring for patients with rheumatoid arthritis\u2013associated interstitial lung disease: an international survey","volume":"61","author":"Solomon","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.rmed.2026.109059_bib23","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00337-2020","article-title":"Methotrexate and rheumatoid arthritis\u2013associated interstitial lung disease","volume":"57","author":"Juge","year":"2021","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.rmed.2026.109059_bib24","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.chest.2022.11.035","article-title":"Treatment outcomes for rheumatoid arthritis-associated interstitial lung disease: a real-world, multisite study of the impact of immunosuppression on pulmonary function trajectory","volume":"163","author":"Matson","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2026.109059_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2026.106997","article-title":"Window of opportunity with abatacept in rheumatoid arthritis-associated interstitial lung disease: a multicentre study of 526 patients","author":"Serrano-Combarro","year":"2026","journal-title":"Eur. J. Intern. Med."},{"issue":"3","key":"10.1016\/j.rmed.2026.109059_bib26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/14740338.2021.1973428","article-title":"Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases","volume":"21","author":"Vicente-Rabaneda","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"issue":"1","key":"10.1016\/j.rmed.2026.109059_bib27","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12931-022-02082-x","article-title":"Effect size of rituximab on pulmonary function in the treatment of connective-tissue disease-related interstitial lung disease: a systematic review and meta-analysis","volume":"23","author":"Zhao","year":"2022","journal-title":"Respir. Res."},{"issue":"1","key":"10.1016\/j.rmed.2026.109059_bib28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2026.109059_bib29","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.2147\/DDDT.S204730","article-title":"Effect of tumor necrosis factor inhibitors on interstitial lung disease in rheumatoid arthritis: angel or demon?","volume":"13","author":"Huang","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"issue":"3","key":"10.1016\/j.rmed.2026.109059_bib30","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1016\/S2665-9913(24)00265-0","article-title":"Advanced therapies in US veterans with rheumatoid arthritis\u2013associated interstitial lung disease: a retrospective, active-comparator, new-user, cohort study","volume":"7","author":"England","year":"2025","journal-title":"Lancet Rheumatol."},{"issue":"1","key":"10.1016\/j.rmed.2026.109059_bib31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","article-title":"Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir. Med."},{"issue":"9","key":"10.1016\/j.rmed.2026.109059_bib32","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1007\/s10067-021-05761-0","article-title":"Use of ultrasound to diagnose and monitor interstitial lung disease in rheumatic diseases","volume":"40","author":"Vicente-Rabaneda","year":"2021","journal-title":"Clin. Rheumatol."},{"issue":"6","key":"10.1016\/j.rmed.2026.109059_bib33","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.chest.2024.11.038","article-title":"Performance of lung ultrasound as a screening tool for subclinical rheumatoid arthritis-associated interstitial lung disease: a multicenter study","volume":"167","author":"Otaola","year":"2025","journal-title":"Chest"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126004270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126004270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:44:04Z","timestamp":1793375044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611126004270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":33,"alternative-id":["S0954611126004270"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2026.109059","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunosuppressive medication patterns in rheumatoid arthritis\u2013associated interstitial lung disease by antifibrotic documentation status: A multicenter U.S. electronic health record study","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2026.109059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109059"}}